Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

8/3/16 – New York Step Therapy Campaign Rally

Aug 05/50SN Staff/ Events

Patients, advocates and health care providers came together on the steps of the state capitol in Albany, NY, August 3rd, to call on Governor Andrew Cuomo to sign into law legislation aimed at ensuring that patients and their doctors have the final say in their medication treatment plans. During this past legislative session, both the […]

READ MORE

GHLF/50-SN activity at FDA Arthritis Advisory Committee Meeting July 12th & July 13th

Jul 18/50SN Staff/ Events

On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]

READ MORE

Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Jul 18/50SN Staff/ GHLF in the news

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

READ MORE

July 12th – GHLF testimony and recommendation to FDA on proposed biosimilar to HUMIRA (adalimumab)

Jul 15/50SN Staff/ FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE

July 13th – GHLF FDA Arthritis Advisory Committee comments on proposed biosimilar to ENBREL (etanercept)

Jul 15/50SN Staff/ FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE